Indeed, GLP-1 analogues may reduce the rewarding effects of palatable food intake (for a review, see also [59]) and the food-related brain responses in both T2DM and obese subjects in insula, amygdala, putamen, and orbitofrontal cortex [62]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.